ATL’s Fill joins pharmaceutical start-up

Article

After brokering the sale of ATL Ultrasound to Royal Philips Electronics of the Netherlands (SCAN 8/5/98), chairman and CEO Dennis Fill has moved on to a new venture. Fill last month was named president and CEO of Cytran, a new

After brokering the sale of ATL Ultrasound to Royal Philips Electronics of the Netherlands (SCAN 8/5/98), chairman and CEO Dennis Fill has moved on to a new venture. Fill last month was named president and CEO of Cytran, a new pharmaceutical company based in Kirkland, WA. Effective March 1, he replaced Cytran’s former CEO, Philip Syrdal. Fill served as CEO of Bothell, WA-based ATL from 1987 through December 1998. Cytran was founded in 1991 and develops peptide compounds for the treatment of cancer and modulation of the immune system.

Recent Videos
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
Incorporating CT Colonography into Radiology Practice
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
What New Interventional Radiology Research Reveals About Treatment for Breast Cancer Liver Metastases
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Pertinent Insights into the Imaging of Patients with Marfan Syndrome
Related Content
© 2025 MJH Life Sciences

All rights reserved.